Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Low frequency of mismatch repair deficiency in gallbladder cancer.

Goeppert B, Roessler S, Renner M, Loeffler M, Singer S, Rausch M, Albrecht T, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M.

Diagn Pathol. 2019 May 8;14(1):36. doi: 10.1186/s13000-019-0813-5.

2.

Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma.

Goeppert B, Renner M, Singer S, Albrecht T, Zhang Q, Mehrabi A, Pathil A, Springfeld C, Köhler B, Rupp C, Weiss KH, Kühl AA, Arsenic R, Pape UF, Vogel A, Schirmacher P, Roessler S, Utku N.

Sci Rep. 2019 Mar 13;9(1):4338. doi: 10.1038/s41598-019-40487-9.

3.

Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.

Kriegsmann M, Roessler S, Kriegsmann K, Renner M, Longuespée R, Albrecht T, Loeffler M, Singer S, Mehrabi A, Vogel MN, Pathil A, Köhler B, Springfeld C, Rupp C, Weiss KH, Goeppert B.

BMC Cancer. 2019 Jan 15;19(1):72. doi: 10.1186/s12885-018-5254-0.

4.

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.

Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Pfeiffenberger J, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M.

Br J Cancer. 2019 Jan;120(1):109-114. doi: 10.1038/s41416-018-0199-2. Epub 2018 Oct 31.

PMID:
30377340
5.

Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization.

Su J, Gan-Schreier H, Goeppert B, Chamulitrat W, Stremmel W, Pathil A.

Int J Mol Sci. 2018 Oct 20;19(10). pii: E3254. doi: 10.3390/ijms19103254.

6.

Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.

Krüger K, Krauth C, Rossol S, Mauss S, Boeker KHW, Müller T, Klinker H, Pathil A, Heyne R, Stahmeyer JT; Collaborators DHC-R.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):230-240. doi: 10.1097/MEG.0000000000001283.

PMID:
30325794
7.

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.

Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C.

Gut. 2019 Jun;68(6):1099-1107. doi: 10.1136/gutjnl-2018-316228. Epub 2018 Aug 1.

PMID:
30068662
8.

Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.

Tiwari-Heckler S, Gan-Schreier H, Stremmel W, Chamulitrat W, Pathil A.

Nutrients. 2018 May 21;10(5). pii: E649. doi: 10.3390/nu10050649.

9.

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.

Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP.

PLoS One. 2018 Jun 6;13(6):e0197544. doi: 10.1371/journal.pone.0197544. eCollection 2018.

10.

Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury.

Ludwig JM, Zhang Y, Chamulitrat W, Stremmel W, Pathil A.

PLoS One. 2018 May 24;13(5):e0197836. doi: 10.1371/journal.pone.0197836. eCollection 2018.

11.

Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting.

Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S.

United European Gastroenterol J. 2018 Mar;6(2):213-224. doi: 10.1177/2050640617716607. Epub 2017 Jun 17.

12.

Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers.

Krawczyk M, Bantel H, Rau M, Schattenberg JM, Grünhage F, Pathil A, Demir M, Kluwe J, Boettler T, Weber SN, Geier A, Lammert F; NAFLD Clinical Study Group (NAFLD CSG).

J Hum Genet. 2018 May;63(5):621-626. doi: 10.1038/s10038-018-0420-4. Epub 2018 Feb 26.

PMID:
29483677
13.

Ursodeoxycholyl lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages.

Horvatova A, Utaipan T, Otto AC, Zhang Y, Gan-Schreier H, Pavek P, Pathil A, Stremmel W, Chamulitrat W.

Eur J Pharmacol. 2018 Apr 15;825:63-74. doi: 10.1016/j.ejphar.2018.02.030. Epub 2018 Feb 20.

PMID:
29475064
14.

Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.

Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A.

World J Gastroenterol. 2018 Feb 21;24(7):852-861. doi: 10.3748/wjg.v24.i7.852.

15.

Role of conventional immunomarkers, HNF4-α and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas.

Kriegsmann M, Harms A, Longuespée R, Muley T, Winter H, Kriegsmann K, Kazdal D, Goeppert B, Pathil A, Warth A.

Histopathology. 2018 May;72(6):997-1006. doi: 10.1111/his.13455. Epub 2018 Feb 20.

PMID:
29243296
16.

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.

Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, Boeker K, Zimmermann T, Teuber G, Vornkahl HP, Simon KG, Niederau C, Wedemeyer H, Zeuzem S.

J Hepatol. 2018 Apr;68(4):663-671. doi: 10.1016/j.jhep.2017.11.009. Epub 2017 Nov 11.

PMID:
29133244
17.

The overall fatty acid absorption controlled by basolateral chylomicron excretion under regulation of p-JNK1.

Stremmel W, Staffer S, Wannhoff A, Pathil A.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):917-928. doi: 10.1016/j.bbalip.2017.05.013. Epub 2017 Jun 6.

18.

The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.

Krawczyk M, Rau M, Grünhage F, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Geier A, Lammert F; NAFLD Clinical Study Group (NAFLD CSG).

Hepatology. 2017 Aug;66(2):666-667. doi: 10.1002/hep.29100. Epub 2017 Jul 4. No abstract available.

PMID:
28176361
19.

Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis.

Utaipan T, Otto AC, Gan-Schreier H, Chunglok W, Pathil A, Stremmel W, Chamulitrat W.

Shock. 2017 Aug;48(2):251-259. doi: 10.1097/SHK.0000000000000831.

PMID:
28060213
20.

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group.

Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28.

PMID:
28029529
21.

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.

Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Lammert F, Geier A; NAFLD Clinical Study Group.

J Lipid Res. 2017 Jan;58(1):247-255. doi: 10.1194/jlr.P067454. Epub 2016 Nov 11.

22.

Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.

Goeppert B, Ernst C, Baer C, Roessler S, Renner M, Mehrabi A, Hafezi M, Pathil A, Warth A, Stenzinger A, Weichert W, Bähr M, Will R, Schirmacher P, Plass C, Weichenhan D.

Epigenetics. 2016 Nov;11(11):780-790. Epub 2016 Sep 3.

23.

Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors.

Niederdöckl J, Dempfle CE, Schönherr HR, Bartsch A, Miles G, Laggner A, Pathil A.

Int J Lab Hematol. 2016 Aug;38(4):426-34. doi: 10.1111/ijlh.12519. Epub 2016 Jul 7.

PMID:
27384253
24.

Cervical esophagotomy for foreign body extraction - Case report and comprehensive review of the literature.

Heger P, Weber TF, Rehm J, Pathil A, Decker F, Schemmer P.

Ann Med Surg (Lond). 2016 Apr 7;7:87-91. doi: 10.1016/j.amsu.2016.04.001. eCollection 2016 May.

25.

Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer.

Goeppert B, Frauenschuh L, Zucknick M, Roessler S, Mehrabi A, Hafezi M, Stenzinger A, Warth A, Pathil A, Renner M, Schirmacher P, Weichert W.

Br J Cancer. 2015 Nov 3;113(9):1343-9. doi: 10.1038/bjc.2015.337. Epub 2015 Oct 13.

26.

Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.

Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A.

BMC Gastroenterol. 2015 Aug 4;15:97. doi: 10.1186/s12876-015-0328-9.

27.

Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.

Pathil A, Liebisch G, Okun JG, Chamulitrat W, Schmitz G, Stremmel W.

Eur J Clin Invest. 2015 Sep;45(9):925-31. doi: 10.1111/eci.12486. Epub 2015 Jul 14.

PMID:
26108973
28.

Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice.

Wang J, Deng X, Yi S, Pathil A, Zhang W, Setchell K, Stremmel W, Chamulitrat W.

Shock. 2015 Apr;43(4):379-86. doi: 10.1097/SHK.0000000000000312.

PMID:
25526375
29.

Ursodeoxycholyl lysophosphatidylethanolamide inhibits cholestasis- and hypoxia-induced apoptosis by upregulating antiapoptosis proteins.

Sellinger M, Xu W, Pathil A, Stremmel W, Chamulitrat W.

Exp Biol Med (Maywood). 2015 Feb;240(2):252-60. doi: 10.1177/1535370214547157. Epub 2014 Aug 14.

30.

Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.

Pathil A, Mueller J, Ludwig JM, Wang J, Warth A, Chamulitrat W, Stremmel W.

Br J Pharmacol. 2014 Nov;171(22):5113-26. doi: 10.1111/bph.12837. Epub 2014 Sep 5.

31.

Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis.

Stremmel W, Staffer S, Wannhoff A, Pathil A, Chamulitrat W.

FASEB J. 2014 Jul;28(7):3159-70. doi: 10.1096/fj.14-249763. Epub 2014 Apr 9.

PMID:
24719358
32.

Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes.

Chamulitrat W, Liebisch G, Xu W, Gan-Schreier H, Pathil A, Schmitz G, Stremmel W.

Mol Pharmacol. 2013 Nov;84(5):696-709. doi: 10.1124/mol.113.088039. Epub 2013 Aug 23.

PMID:
23974795
33.

The influence of haemodialysis on haemodynamic measurements using transpulmonary thermodilution in patients with septic shock: an observational study.

Pathil A, Stremmel W, Schwenger V, Eisenbach C.

Eur J Anaesthesiol. 2013 Jan;30(1):16-20. doi: 10.1097/EJA.0b013e328358543a.

PMID:
22935958
34.

Hepatoprotectant ursodeoxycholyl lysophosphatidylethanolamide increasing phosphatidylcholine levels as a potential therapy of acute liver injury.

Chamulitrat W, Zhang W, Xu W, Pathil A, Setchell K, Stremmel W.

Front Physiol. 2012 Feb 20;3:24. doi: 10.3389/fphys.2012.00024. eCollection 2012.

35.

Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.

Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W.

Hepatology. 2012 May;55(5):1369-78. doi: 10.1002/hep.25531. Epub 2012 Mar 18.

PMID:
22183915
36.

Comparison of different bile acid-phospholipid conjugates in acute hepatitis.

Pathil A, Warth A, Chamulitrat W, Stremmel W.

Eur J Clin Invest. 2012 Feb;42(2):130-8. doi: 10.1111/j.1365-2362.2011.02563.x. Epub 2011 Jun 27.

PMID:
21707612
37.

Loss of aquaporin-4 expression and putative function in non-small cell lung cancer.

Warth A, Muley T, Meister M, Herpel E, Pathil A, Hoffmann H, Schnabel PA, Bender C, Buness A, Schirmacher P, Kuner R.

BMC Cancer. 2011 May 6;11:161. doi: 10.1186/1471-2407-11-161.

38.

The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury.

Pathil A, Warth A, Chamulitrat W, Stremmel W.

J Hepatol. 2011 Apr;54(4):674-84. doi: 10.1016/j.jhep.2010.07.028. Epub 2010 Sep 27.

PMID:
21146893
39.

Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.

Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W.

Hepatology. 2009 Jul;50(1):143-54. doi: 10.1002/hep.22955.

PMID:
19496180
40.

Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.

Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M.

Cancer. 2007 May 15;109(10):2132-41.

41.

HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.

Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M.

Hepatology. 2006 Mar;43(3):425-34.

PMID:
16583461
42.

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR.

Cancer Res. 2005 Jul 15;65(14):6321-9.

43.

Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.

Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M.

J Hepatol. 2005 Feb;42(2):210-7.

PMID:
15664246

Supplemental Content

Loading ...
Support Center